Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 7.1% – Should You Sell?

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) were down 7.1% during trading on Monday . The stock traded as low as $24.12 and last traded at $24.5730. Approximately 673,841 shares were traded during trading, a decline of 46% from the average session volume of 1,238,818 shares. The stock had previously closed at $26.44.

Analysts Set New Price Targets

CAPR has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Monday, June 15th. B. Riley Financial raised their target price on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Cantor Fitzgerald set a $62.00 price target on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a report on Friday, March 13th. LADENBURG THALM/SH SH raised Capricor Therapeutics to a “strong-buy” rating in a research report on Thursday. Finally, Piper Sandler reiterated an “overweight” rating and set a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $50.30.

Capricor Therapeutics Stock Down 10.1%

The company’s 50 day moving average price is $30.00 and its 200 day moving average price is $28.41. The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of -10.22 and a beta of 0.39.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). As a group, analysts expect that Capricor Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Insider Activity at Capricor Therapeutics

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total value of $753,250.00. Following the completion of the transaction, the chief financial officer directly owned 8,223 shares of the company’s stock, valued at approximately $247,758.99. The trade was a 75.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Karimah Es Sabar sold 61,265 shares of the firm’s stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $30.17, for a total transaction of $1,848,365.05. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 173,429 shares of company stock valued at $5,329,440. 9.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. boosted its stake in shares of Capricor Therapeutics by 39.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock worth $3,902,000 after acquiring an additional 116,373 shares in the last quarter. Legal & General Group Plc raised its holdings in Capricor Therapeutics by 8.4% in the 2nd quarter. Legal & General Group Plc now owns 41,273 shares of the biotechnology company’s stock worth $410,000 after purchasing an additional 3,205 shares during the period. Rhumbline Advisers raised its holdings in Capricor Therapeutics by 7.3% in the 2nd quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company’s stock worth $531,000 after purchasing an additional 3,636 shares during the period. Marshall Wace LLP purchased a new position in Capricor Therapeutics during the second quarter worth approximately $796,000. Finally, Jump Financial LLC boosted its position in Capricor Therapeutics by 42.6% during the second quarter. Jump Financial LLC now owns 232,536 shares of the biotechnology company’s stock worth $2,309,000 after purchasing an additional 69,515 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.